Tradestie Institutional Equity Comparison Engine
ATHA vs BIIB โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BIIB Overall Edge
BIIB Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, ATHA trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus BIIB at 15.6x Forward P/E and 23.5% operating margin (+10.6% YoY). In options structure, ATHA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
BIIB
ATHA N/M vs BIIB 15.6x Fwd P/E
Growth & Margin Winner
BIIB
Op Margin 0.0% vs 23.5% ยท YoY +0.0% vs +10.6%
Momentum & Technical Winner
BIIB
1Y +12.5% vs +53.4% ยท 52W Pos 80% vs 92%
Options & Structure Winner
BIIB
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (6th %ile IV)
ATHA
NASDAQ
Athira Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$6.75
-6.12% 1D
Market Cap
$26.6M
1M Return
+73.75%
1Y Return
+12.5%
Forward P/E
N/M
Unified AI Score
56.2 / 100
HOLD
Tech 55.0
Fund 52.0
Flow 50.0
Mom 50.0
BIIB
NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap
$37.0B
1M Return
+8.63%
1Y Return
+53.41%
Forward P/E
15.6x
Unified AI Score
50.2 / 100
HOLD
Tech 45.0
Fund 52.0
Flow 64.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
ATHA +12.5%
BIIB +53.41%
Spread: +29.87 pp (ATHA Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
ATHA TTM Op. Margin: 0.0%
BIIB TTM Op. Margin: 23.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ATHA vs BIIB. Trailing 12-month operating profitability (ATHA 0.0% vs BIIB 23.5%) and valuation multiples (ATHA N/M vs BIIB 15.6x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | ATHA | BIIB | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $26.6M | $37.0B | Larger Scale | BIIB |
| Trailing P/E Ratio Valuation | N/M | 109.9x | Lower Multiple | BIIB |
| Forward P/E Ratio Valuation | N/M | 15.6x | Lower Multiple | BIIB |
| Revenue Growth (YoY) Growth | +0.0% | +10.6% | Higher Growth | BIIB |
| Operating Margin (TTM) Profitability | 0.0% | 23.5% | Higher Margin | BIIB |
| Net Profit Margin Profitability | 0.0% | 3.4% | Higher Margin | BIIB |
| Return on Equity (ROE) Capital Efficiency | -89.4% | 1.9% | Higher ROE | BIIB |
| 52-Week Range Position Momentum | 80% ($0โ$8) | 92% ($160โ$261) | Stronger Trend | BIIB |
| Beta / 30D Volatility Risk Regime | 6.17ฮฒ ยท 241% Vol | 0.27ฮฒ ยท 36% Vol | Lower Realized Risk | BIIB |
| Unified Institutional Score Composite Signal | 56.2 / 100 (HOLD) | 50.2 / 100 (HOLD) | Higher Composite | ATHA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full ATHA vs BIIB Buy Guide
ATHA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
BIIB
CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
6th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither ATHA nor BIIB registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.